The grounds for recalling Oxbryta stem from deeply concerning clinical findings. In a study involving children, eight deaths were reported in the Oxbryta group compared to just two deaths in the control group. Similarly, a study of adolescents and adults documented eight deaths among those taking the drug. These statistics highlight the serious risks patients face and raise critical questions about the manufacturer’s transparency and accountability.
Over 100 adverse events related to Oxbryta have been reported to the FDA since its approval.
Patients with sickle cell disease already face a 2.5 times higher risk of early death, making any additional risk from medication unacceptable.
Liver Damage (Elevated ALT/AST Levels)
Anemia Worsening
Severe Fatigue
Jaundice (Yellowing of Skin or Eyes)
Gastrointestinal Issues (Nausea, Diarrhea)
Allergic Reactions
Click the red button below.
Answer a few quick questions on the next page (takes 30 seconds).